Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center

Margret B. Einarson 博士，福克斯蔡斯癌症中心高通量筛查设施经理

• 批准号: 10005259
• 负责人: MARGRET B EINARSON
• 金额: $ 12.84万
• 依托单位: RESEARCH INST OF FOX CHASE CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005259
• 关键词: Animal Model; Biochemical; Biological Markers; Cancer Burden; Cancer Center Support Grant; Cancer Patient; Comprehensive Cancer Center; Data; Disease; Doctor of Philosophy; Equipment; Faculty; Fox Chase Cancer Center; Goals; Grant; Grant Review; Guava Fruit; Individual; Laboratories; Libraries; Maintenance; Molecular; Patients; Preparation; Procedures; Publications; RNA Interference; Research; Research Personnel; Reservations; Resources; Sampling; Surveys; Technology; Time; assay development; complement resource; high throughput screening; instrumentation; new technology; novel therapeutics; screening

Project Summary I am the Manager of the High Throughput Screening Facility (HTSF) at the NCI-designated comprehensive cancer center Fox Chase Cancer Center (FCCC). The HTSF provides screening platforms and specialized instrumentation for increased experimental throughput. In particular, the HTSF allows investigators to utilize RNAi and compound libraries, and the specialized instrumentation required for large scale screening with these resources. I have been the Manager of the HTSF since its inception, and have guided the establishment and maintenance of every aspect of the facility. I managed the acquisition of a suite of HTS equipment and libraries, established all the standard operating procedures (SOPs) and created a working pipeline from assay development to statistical hit-picking for investigators. After the establishment of the HTSF under my management, on its first review by the NCI in 2010 as a proposed facility for addition to the Cancer Center Support Grant (CCSG), it was rated as “Outstanding.” Overall, the vitality of the resource I have created for molecular screening is evidenced by forty-four publications that have utilized the HTSF between the years 2007- 2015. Within the most recent CCSG review period (2011-2014), there was a three-fold increase in the total number of publications over the first CCSG review period. During this time period, there was an average of over one thousand individual reservations for equipment use per annum. These data indicate that the resources I have established and continue to develop are robust and a pivotal scientific asset for the laboratories at FCCC. As technologies and research directions evolve, I have surveyed the faculty to identify new technology platforms for the HTSF, and I have led the preparation of two S10 shared instrumentation grants two successful S10 applications allowing the purchase of the Guava EasyCyte benchtop FACS, and a Luminex 100/200, multiplexing biomarker analyzer. The acquisition of this new technology platform will complement the resources available to screeners, but crucially allow the HTSF to serve investigators utilizing patient samples and animal models. My efforts supporting and implementing the technologies provided in the HTSF is crucial to their continued excellence and availability.

项目概要 我是 NCI 指定综合实验室高通量筛选设施 (HTSF) 的经理 癌症中心福克斯蔡斯癌症中心 (FCCC)。 HTSF 提供筛选平台和专门的 提高实验通量的仪器。特别是，HTSF 允许调查人员利用 RNAi 和化合物库，以及大规模筛选所需的专用仪器 资源。自 HTSF 成立以来，我一直担任经理，并指导了 HTSF 的建立和 设施各个方面的维护。我管理了一套 HTS 设备和库的采购， 建立了所有标准操作程序 (SOP) 并从分析中创建了工作流程 为调查人员开发统计命中选择。在我的领导下成立 HTSF 后 管理层于 2010 年首次接受 NCI 审查，将其作为癌症中心增建的拟议设施 支持补助金（CCSG），被评为“优秀”。总的来说，我所创建的资源的生命力 2007 年至 2007 年期间，有 44 份出版物利用了 HTSF，证明了分子筛选的有效性 2015 年。在最近的 CCSG 审查期间（2011-2014 年），总数增加了三倍 第一个 CCSG 审查期间的出版物数量。在此期间，平均有超过 每年有一千个个人设备使用预订。这些数据表明我的资源 已经建立并继续发展是FCCC实验室的强大和关键的科学资产。 随着技术和研究方向的发展，我对教师进行了调查，以确定新技术平台 对于 HTSF，我领导了两个 S10 共享仪器的准备工作，并资助了两个成功的 S10 允许购买 Guava EasyCyte 台式 FACS 和 Luminex 100/200、多路复用的应用程序 生物标志物分析仪。收购这一新技术平台将补充可用资源 筛查人员，但至关重要的是允许 HTSF 利用患者样本和动物模型为研究人员提供服务。我的 支持和实施 HTSF 中提供的技术的努力对于他们的持续发展至关重要 卓越性和可用性。